GBT heads to FDA with sickle cell drug voxelotorGlobal Blood Therapeutics (GBT) has persuaded the FDA to accept biomarker data from a phase III trial of Share XGBT heads to FDA with sickle cell drug voxelotorhttps://pharmaphorum.com/news/gbt-heads-to-fda-with-sickle-cell-drug-voxelotor/
